News Release

Long Term Efficacy and Safety Study accepted

Date: Mar 27, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that it has received from Health Canada its 'NO OBJECTION LETTER'. This allows patients participating in our clinical trials and who receive benefit from the drug to continue having access to it.

This is a multi-centre, open label, multi-dose long term safety and efficacy study of Tetrodotoxin (TTX). The study will include all centers where previously and prospectively TTX has been involved in a clinical study phase. All participants will be closely monitored and must go through an inclusion and exclusion criteria per treatment cycle.

Mr. Frank Shum, Chairman and CEO said, "I am delighted with this good news from Health Canada as we thought and obviously Health Canada did also, that this was the only morally, decent and responsible way to proceed."

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.